Work

Best evidence summary for preventing and preventing epidermal growth factor receptor inhibitors induced paronychia in cancer patients

Year: 2025

Type: article

Abstract: Objective: To evaluate and summarize the best evidence for preventing and managing epidermal growth factor receptor inhibitors induced paronychia in cancer patients. It aims to provide a reference for medical staff. Methods: We systematically searched for evidence on paronychia symptoms in 14 databases such as Cnki、Wanfang, 7 guide websites such as GIN and NZGG, and 8 professional websites such as UICC and ACS from database establishment to August 2024. Two researchers evaluated the quality of the literature and extracted the data. Results: A total of 20 articles were included in this study, including 5 clinical decisions、5 guidelines、3 evidence summaries 、3 recommended practices, and 4 experts consensuses. Finally, 12 pieces of evidence were summarized from 4 aspects, including risk factor assessment, professional healthcare training, preventive measures, and therapeutic measures. Conclusion: Our research summarizes the best evidence for preventing and managing epidermal growth factor receptor inhibitors induced by paronychia in cancer patients. In the actual clinical application, it is necessary to fully consider the clinical situation, combine the judgment of professionals and patients' wishes, follow the principle of individualization, analyze the obstacles and facilitating factors of the application of evidence, and apply the evidence to the clinical practice prudently.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2025.1555114

Authors: Kexuan Li, Xiuyue Qiu, Jiayu Zhang, Yingshuyi Zhou, Youfen Fan

Institutions: Ningbo No. 2 Hospital, Zhejiang Chinese Medical University

Language: English

Topic: Chemotherapy-related skin toxicity

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801